Kendall Capital Partners
SelectiveBoston, MABiotechnology, Healthcare, PharmaceuticalsLast fund filed April 2021
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Kendall Capital Partners I, L.P. | April 2021 | Indefinite | $8.7M | 12 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
3 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Zhu | Slowing | Biotech & pharma | 4 | 1 |
Classified sectors of Kendall Capital Partners’s own portfolio companies, based on 40 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Polaris Partners | 7 | Arsenal Medical, Glympse Bio, Microchips Biotech, Seer Biosciences, SELECTA BIOSCIENCES, SQZ Biotechnologies, Suono Bio |
| ARCH Venture Partners | 1 | eGenesis |
| Atlas Venture | 1 | Kala Pharmaceuticals |
| Caduceus Capital |
| George Church | Slowing | AI & machine learning, Biotech & pharma | 2 | 1 |
| Robert Langer | Quiet | Biotech & pharma, Medical devices, Digital health | 37 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Kendall Capital Partners’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 1 |
| SELECTA BIOSCIENCES |
| CRV | 1 | Glympse Bio |
| Lux Capital | 1 | Kala Pharmaceuticals |
| New Enterprise Associates | 1 | XTuit Pharmaceuticals |
| Orbimed Asia Partners | 1 | SELECTA BIOSCIENCES |
| Orbimed Genesis | 1 | SELECTA BIOSCIENCES |
| Orbimed Global Healthcare | 1 | SELECTA BIOSCIENCES |
| Orbimed Israel Partners | 1 | SELECTA BIOSCIENCES |
| Orbimed New Horizons | 1 | SELECTA BIOSCIENCES |
| Orbimed Partners | 1 | SELECTA BIOSCIENCES |
| Orbimed Private Investments | 1 | SELECTA BIOSCIENCES |
| Third Rock Ventures | 1 | Kala Pharmaceuticals |
A shared board seat: a company where filings name a Kendall Capital Partners partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.